Top Markets
#1 Akedo Akedo +12.06%
#2 MarsCoin MarsCoin +11.66%
#3 EXOD EXOD +9.04%
#4 Solstice Solstice +8.28%
#5 ETHGas ETHGas +7.54%
#6 龙虾 (Lobster) 龙虾 (Lobster) +6.80%
#7 Seeker Seeker +5.97%
#8 DexNet DexNet +5.76%
#9 peaq peaq +5.53%
#10 Official Trump Official Trump +5.49%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Damora Therapeutics, Inc. Damora Therapeutics, Inc.

Damora Therapeutics, Inc.

DMRA
Rank in Stocks #6692
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering... Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
Share Price
$30.90
Last synced: 2026-08-27
Market Cap
$1.90B
Change (1 day)
1.68%
Change (1 year)
859.63%
Country
US
Trade Damora Therapeutics, Inc. (DMRA)

Category

Healthcare
P/E ratio for Damora Therapeutics, Inc. (DMRA)
P/E ratio as of 2026 TTM: 0
According to Damora Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Damora Therapeutics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.